Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy

• Published in: The Prostate Vol. 71; no. 3; pp. 326 - 331
• Main Authors: Zhang, Hai-Liang, Yang, Li-Feng, Zhu, Yao, Yao, Xu-Dong, Zhang, Shi-Lin, Dai, Bo, Zhu, Yi-Ping, Shen, Yi-Jun, Shi, Guo-Hai, Ye, Ding-Wei
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.02.2011; Wiley-Liss
• Subjects: Aged; Antineoplastic Agents - therapeutic use; Biological and medical sciences; chemotherapy; Gynecology. Andrology. Obstetrics; hormone refractory; Humans; Male; Male genital diseases; Medical sciences; MicroRNA-21; MicroRNAs - blood; Middle Aged; Neoplasms, Hormone-Dependent - drug therapy; Neoplasms, Hormone-Dependent - genetics; Nephrology. Urinary tract diseases; predictive factor; prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Taxoids - therapeutic use; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Antineoplastic agent; Andrology; Nephrology; RNA interference; Prostate disease; Hormone therapy; Metastasis; hormone refractory; Taxane derivatives; Advanced stage; Serum; Antimitotic; Male genital diseases; Human; Treatment resistance; Urinary system disease; Treatment efficiency; Gynecology; Docetaxel; Micro RNA; Malignant tumor; Gene silencing; Chemotherapy; Treatment; Metastatic; MicroRNA-21; Predictive factor; Prostate cancer; Cancer

BACKGROUND miR‐21 has been recognized as an “onco‐microRNA” with the activity of negatively modulating the expression of tumor‐suppressor genes. However, its role in prostate cancer (CaP) has not been well‐documented. We designed this study to assess the potential function of serum miR‐21 in the pro...